Evidence map›Paper›PMID 12759256›Full record

ArticleThe American journal of pathology2003

Febrile-range hyperthermia augments pulmonary neutrophil recruitment and amplifies pulmonary oxygen toxicity.

Jeffrey D Hasday, Allen Garrison, Ishwar S Singh, Theodore Standiford, Garrettson S Ellis, Srinivas Rao, Ju-Ren He, Penny Rice, Mariah Frank, Simeon E Goldblum and 1 more

2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03376854 phase2withdrawnnot on this mapstarted 2018, after this paper: background citation

Pilot Randomized Clinical Trial of Therapeutic Hypothermia Plus Neuromuscular Blockade vs. Standard of Care in COVID-19 Patients With Moderate to Severe ARDS - the Cooling to Help Injured Lungs (CHILL) Pilot Study

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2018 to 2021Enrolled0ConditionsRespiratory Distress Syndrome, Adult, Sars-CoV2ArmsHypothermia, Neuromuscular Blocking Agents, Standard of Care
NCT04545424 phase2recruitingnot on this mapstarted 2021, after this paper: background citation

Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients With ARDS

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2021 to 2026Enrolled340ConditionsRespiratory Distress Syndrome, AdultArmsHypothermia, Neuromuscular Blocking Agents, Standard of care
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 72 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Temperature control in sepsis.Frontiers in medicine · 2023
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Fever: Views in Anthroposophic Medicine and Their Scientific Validity.Evidence-based complementary and alternative medicine : eCAM · 2016
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jeffrey D HasdayDivisions of Pulmonary and Critical Care Medicine, Department of Pathology, University of Maryland, Baltimore, Maryland 21201, USA. jhasday@umaryland.edu
Allen Garrison
Ishwar S Singh
Theodore Standiford
Garrettson S Ellis
Srinivas Rao
Ju-Ren He
Penny Rice
Mariah Frank
Simeon E Goldblum
Rose M Viscardi
University of Maryland, Baltimore · USArc of the United States · USUnited States Department of Veterans Affairs · USUniversity of Michigan–Ann Arbor · US

Funding

p38MAP kinase-dependent mechanisms of fever-enhanced acute lung injuryR01HL069057 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI HASDAY, JEFFREY D, SHAPIRO, PAUL S · 2003 to 2016
$4.6M
BODY TEMPERATURE AND REGULATING HOST DEFENSESR01AI042117 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HASDAY, JEFFREY D · 1999 to 2001
$418k
NHLBI NIH HHS R01 HL069057NIAID NIH HHS AI42117
6 · The paper itself

Abstract

Febrile-range hyperthermia (FRH) improves survival in experimental infections by accelerating pathogen clearance, but may also increase collateral tissue injury. We hypothesized that FRH would worsen the outcome of inflammation stimulated by a non-replicating agonist and tested this hypothesis in a murine model of pulmonary oxygen toxicity. Using a conscious, temperature-controlled mouse model, we showed that maintaining a core temperature at FRH (39 degrees C to 40 degrees C) rather than at euthermic levels (36.5 degrees C to 37 degrees C) during hyperoxia exposure accelerated lethal pulmonary vascular endothelial injury, reduced the inspired oxygen threshold for lethality, induced expression of granulocyte-colony stimulating factor, and expanded the circulating neutrophil pool. In these same mice, FRH augmented pulmonary expression of the ELR(+) CXC chemokines, KC and LPS-induced CXC chemokine, enhanced recruitment of neutrophils, and changed the histological pattern of lung injury to a neutrophilic interstitial pneumonitis. Immunoblockade of CXC receptor-2 abrogated neutrophil recruitment, reduced pulmonary vascular injury, and delayed death. These combined data demonstrate that FRH may enlist distinct mediators and effector cells to profoundly shift the host response to a defined injurious stimulus, in part by augmenting delivery of neutrophils to sites of inflammation, such as may occur in infections. In certain conditions, such as in the hyperoxic lung, this process may be deleterious.

Indexed as

Neutrophil Infiltration3T3 CellsAnimalsBody TemperatureBronchoalveolar Lavage FluidCell LineCytokinesHyperoxiaHyperthermia, InducedLeukocyte CountLungLung Diseases, InterstitialMaleMiceNeutrophilsSurvival RateCytokines

Identifiers

PMID12759256
PMCPMC1868125
OpenAlexW2046981685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.